Publications by authors named "Helmut Oettle"

Claim this Profile
B
Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial.
Rainer Fietkau, Michael Ghadimi, Robert Grützmann, Uwe A Wittel, Lutz Jacobasch, Helmut Oettle

J Clin Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial.
Klara Dorman, Stefan Boeck, Karel Caca, Maximilian Reichert, Thomas J Ettrich, Helmut Oettle

Lancet Gastroenterol Hepatol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116).
Dominik Paul Modest, Volker Heinemann, Philipp Schütt, Stefan Angermeier, Mike Haberkorn, Helmut Oettle

J Cancer Res Clin Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KRT81 and HNF1A expression in pancreatic ductal adenocarcinoma: investigation of predictive and prognostic value of immunohistochemistry-based subtyping.
Jia Rao, Marianne Sinn, Uwe Pelzer, Hanno Riess, Helmut Oettle

J Pathol Clin Res· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma: The HEAT randomised clinical trial.
Rolf D Issels, Stefan Boeck, Uwe Pelzer, Ulrich Mansmann, Pirus Ghadjar, Helmut Oettle

Eur J Cancer· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual Targeting of the EGFR/HER2 Pathway in Combination with Systemic Chemotherapy in Refractory Pancreatic Cancer-The CONKO-008 Phase I Investigation.
Jana K Striefler, Jens M Stieler, Christopher C M Neumann, Dominik Geisel, Pirus Ghadjar, Helmut Oettle

J Clin Med· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression.
Phyllis F Cheung, JiaJin Yang, Rui Fang, Arianna Borgers, Kirsten Krengel, Helmut Oettle

Nat Commun· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study.
Jana Käthe Striefler, Hanno Riess, Philipp Lohneis, Sven Bischoff, Annika Kurreck, Helmut Oettle

Front Oncol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma - A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials.
Annika Kurreck, Johanna Weckwerth, Dominik P Modest, Jana K Striefler, Marcus Bahra, Helmut Oettle

Eur J Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 Trial.
Marianne Sinn, Bruno V Sinn, Denise Treue, Ulrich Keilholz, Frederik Damm, Helmut Oettle

Clin Cancer Res· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer.
Davide Melisi, Rocio Garcia-Carbonero, Teresa Macarulla, Denis Pezet, Gael Deplanque, Helmut Oettle

Br J Cancer· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma.
Philipp Lohneis, Marianne Sinn, Fritz Klein, Sven Bischoff, Jana K Striefler, Helmut Oettle

Br J Cancer· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial.
Marianne Sinn, Marcus Bahra, Torsten Liersch, Klaus Gellert, Helmut Messmann, Helmut Oettle

J Clin Oncol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma.
Philipp Lohneis, Marianne Sinn, Sven Bischoff, Anja Jühling, Uwe Pelzer, Helmut Oettle

Eur J Cancer· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients with Advanced Pancreatic Cancer and Hyperbilirubinaemia: Review and German Expert Opinion on Treatment with nab-Paclitaxel plus Gemcitabine.
Arndt Vogel, Frank Kullmann, Volker Kunzmann, Salah-Eddin Al-Batran, Helmut Oettle

Oncol Res Treat· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Administration of Gemcitabine After Pancreatic Tumor Resection in Mice Induces an Antitumor Immune Response Mediated by Natural Killer Cells.
Engin Gürlevik, Bettina Fleischmann-Mundt, Jennifer Brooks, Ihsan Ekin Demir, Katja Steiger, Helmut Oettle

Gastroenterology· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment.
Jana K Striefler, Marianne Sinn, Uwe Pelzer, Anja Jühling, Lilianna Wislocka, Helmut Oettle

Pathol Res Pract· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gemcitabine-resistant pancreatic cancer: a second-line option.
Helmut Oettle, Thorsten Lehmann

Lancet· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic significance of DNA cytometry for adjuvant therapy response in pancreatic cancer.
Fritz Klein, Marcus Bahra, Anja Schirmeier, Hussein Al-Abadi, Johann Pratschke, Helmut Oettle

J Surg Oncol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial.
Uwe Pelzer, Bernhard Opitz, Gerd Deutschinoff, Martina Stauch, Peter C Reitzig, Helmut Oettle

J Clin Oncol· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nab-paclitaxel for metastatic pancreatic cancer: clinical outcomes and potential mechanisms of action.
Salah-Eddin Al-Batran, Michael Geissler, Thomas Seufferlein, Helmut Oettle

Oncol Res Treat· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progress in the knowledge and treatment of advanced pancreatic cancer: from benchside to bedside.
Helmut Oettle

Cancer Treat Rev· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.
Helmut Oettle, Hanno Riess, Jens M Stieler, Gerhard Heil, Ingo Schwaner

J Clin Oncol· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does long-term survival in patients with pancreatic cancer really exist? Results from the CONKO-001 study.
Marianne Sinn, Jana K Striefler, Bruno V Sinn, Daniel Sallmon, Sven Bischoff, Helmut Oettle

J Surg Oncol· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.
Helmut Oettle, Peter Neuhaus, Andreas Hochhaus, Jörg Thomas Hartmann, Klaus Gellert

JAMA· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis